The use of GEM models for experimental cancer therapeutics
- 26 September 2008
- journal article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 1 (2-3), 83-86
- https://doi.org/10.1242/dmm.000570
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- A Mouse to Human Search for Plasma Proteome Changes Associated with Pancreatic Tumor DevelopmentPLoS Medicine, 2008
- Maximizing mouse cancer modelsNature Reviews Cancer, 2007
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapiesCancer Cell, 2006
- Paradoxical roles of the immune system during cancer developmentNature Reviews Cancer, 2006
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabineEuropean Journal of Pharmacology, 2004
- The Three Es of Cancer ImmunoeditingAnnual Review of Immunology, 2004
- Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude miceWorld Journal of Gastroenterology, 2004
- Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouseCancer Cell, 2003
- Antiangiogenic therapy of experimental cancer does not induce acquired drug resistanceNature, 1997